JAZZ Jazz Pharmaceuticalsdata gap · 72% coveragelimited data
Health Care · Pharmaceuticals · close $210.23 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Jazz Pharmaceuticals (JAZZ) has a ThetaGrade House Rating of 59/100 (grade C), ranking #68 of 150 in Health Care. Its strongest pillars are cash flow (95) and valuation (79); its weakest is balance sheet (32). Data gap: 4 factors without usable data, so 72% of the method weight is covered. TTM revenue growth is 12.6% and operating margin 19.5%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, EPS growth YoY (TTM), 4Q gross-margin change. Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 72% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 47| Revenue growth YoY (TTM) (22.2%) | 12.6% | 59 |
| EPS growth YoY (TTM) (0.0%)data gap | — | — |
| Revenue acceleration (11.1%) | -3.5% | 24 |
Profitability
weight 18.5% (→20.0%) · 67| Operating margin (20.0%) | 19.5% | 67 |
| 4Q gross-margin change (0.0%)data gap | — | — |
Balance sheet
weight 18.5% (→20.0%) · 32| Net debt / EBITDA (10.7%) | 2.91× | 28 |
| Current ratio (5.3%) | 1.78 | 36 |
| Interest coverage (4.0%) | 3.61× | 37 |
Cash flow
weight 12.33% (→13.3%) · 95| FCF margin (6.7%) | 30.4% | 93 |
| FCF yield (6.7%) | 9.5% | 97 |
Valuation
weight 12.33% (→13.3%) · 79| P/E (inverted) (6.7%) | 14.37× | 93 |
| EV/Sales (inverted) (6.7%) | 3.56× | 65 |
Technicals (EOD)
| RSI(14) | 27.4 |
| EMA 9 / 21 | 217.59 / 226.16 |
| 200-day SMA | 214.47 |
| Volume vs 20d avg | 0.72× |
| 20-day return | -13.8% |
Exit-rule monitor
- EXITRating break: House Rating below 60
- WATCHTrend: close below 200-day average
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Operating income: OperatingIncomeLoss · Interest expense: InterestPaidNet · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like JAZZ's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is JAZZ's House Rating?
- JAZZ scores 59 out of 100 (grade C) as of 2026-10-16, ranking #68 of 150 Health Care stocks we cover.
- What do analysts say about JAZZ?
- We do not have enough analyst-sentiment data to score this stock.
- When does JAZZ report earnings next?
- JAZZ's next earnings report is estimated for about 2026-11-04 (window 2026-11-01 to 2026-11-07), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is JAZZ a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology